Caricamento...
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Medicines that activate cannabinoid CB(1) and CB(2) receptor are already in the clinic. These are Cesamet® (nabilone), Marinol® (dronabinol; Δ(9)-tetrahydrocannabinol) and Sativex® (Δ(9)-tetrahydrocannabinol with cannabidiol). The first two of these medicines can be prescribed to reduce chemotherapy...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Publishing Ltd
2009
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2697681/ https://ncbi.nlm.nih.gov/pubmed/19226257 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2008.00048.x |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|